Back to search

Article

Developing peptide-based inhibitors of amylin aggregation as a novel treatment for type 2 diabetes

2017-01-01

Abstract excerpt

Human islet amyloid polypeptide (hIAPP), also known as amylin, is the main constituent of the amyloid deposits present in approximately 95% of people with type 2 diabetes. Amylin aggregates into oligo-/polymeric sheet structures which are considered to be cytotoxic to pancreatic -cells. Inhibiting the early stages of amylin aggregation could provide a potential therapeutic strategy for the treatment of type 2 diab...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8e35cf2d-b3b7-563b-88b2-82207c8285e4
DOI
10.17635/lancaster/thesis/149
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Developing peptide-based inhibitors of amylin aggregation as a novel treatment for type 2 diabetesDOI 10.17635/lancaster/thesis/149
Select a neighboring publication to make it the new centre.